181 related articles for article (PubMed ID: 7914482)
1. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes.
Ma D; Alizadeh H; Comerford SA; Gething MJ; Sambrook JF; Anand R; Niederkorn JY
Curr Eye Res; 1994 May; 13(5):361-9. PubMed ID: 7914482
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice.
Ma D; Niederkorn JY
Invest Ophthalmol Vis Sci; 1995 May; 36(6):1067-75. PubMed ID: 7730016
[TBL] [Abstract][Full Text] [Related]
3. Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye.
Knisely TL; Niederkorn JY
Cancer Immunol Immunother; 1990; 30(6):323-30. PubMed ID: 2302723
[TBL] [Abstract][Full Text] [Related]
4. Capacity of simian virus 40 T antigen to induce self-tolerance but not immunological privilege in the anterior chamber of the eye.
Ma D; Comerford S; Bellingham D; Sambrook J; Gething MJ; Alizadeh H; Anand R; Mellon J; Niederkorn JY
Transplantation; 1994 Mar; 57(5):718-25. PubMed ID: 8140635
[TBL] [Abstract][Full Text] [Related]
5. In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber.
Benson JL; Niederkorn JY
Immunology; 1991 Sep; 74(1):153-9. PubMed ID: 1937568
[TBL] [Abstract][Full Text] [Related]
6. CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism.
Dace DS; Chen PW; Niederkorn JY
J Immunol; 2007 May; 178(10):6115-22. PubMed ID: 17475837
[TBL] [Abstract][Full Text] [Related]
7. Termination of immune privilege in the anterior chamber of the eye when tumor-infiltrating lymphocytes acquire cytolytic function.
Ksander BR; Mammolenti MM; Streilein JW
Transplantation; 1991 Jul; 52(1):128-33. PubMed ID: 1907041
[TBL] [Abstract][Full Text] [Related]
8. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
9. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
[TBL] [Abstract][Full Text] [Related]
10. Role of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.
Ligocki AJ; Brown JR; Niederkorn JY
J Leukoc Biol; 2016 May; 99(5):735-47. PubMed ID: 26578649
[TBL] [Abstract][Full Text] [Related]
11. Anti-leukocyte function-1 antibody treatment prevents the rejection of intraocular regressor tumors and their metastases.
Li XY; Mayhew E; Niederkorn JY
Curr Eye Res; 1995 Aug; 14(8):719-26. PubMed ID: 8529408
[TBL] [Abstract][Full Text] [Related]
12. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
[TBL] [Abstract][Full Text] [Related]
13. Complete elimination ('cure') of progressively growing intraocular tumors by local injection of tumor-specific CD8+ T lymphocytes.
Miki S; Ksander B; Streilein JW
Invest Ophthalmol Vis Sci; 1993 Dec; 34(13):3622-34. PubMed ID: 8258521
[TBL] [Abstract][Full Text] [Related]
14. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
15. Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye.
Wang S; Boonman ZF; Li HC; He Y; Jager MJ; Toes RE; Niederkorn JY
J Immunol; 2003 Sep; 171(6):2789-96. PubMed ID: 12960299
[TBL] [Abstract][Full Text] [Related]
16. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
17. Differential in situ expansion and gene expression of CD4+ and CD8+ tumor-infiltrating lymphocytes following adoptive immunotherapy in a murine tumor model system.
Evans R; Duffy TM; Kamdar SJ
Eur J Immunol; 1991 Aug; 21(8):1815-9. PubMed ID: 1907916
[TBL] [Abstract][Full Text] [Related]
18. Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte.
Tahara H; Fujio K; Araki Y; Setoguchi K; Misaki Y; Kitamura T; Yamamoto K
J Immunol; 2003 Aug; 171(4):2154-60. PubMed ID: 12902522
[TBL] [Abstract][Full Text] [Related]
19. Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis.
Schurmans LR; Diehl L; den Boer AT; Sutmuller RP; Boonman ZF; Medema JP; van der Voort EI; Laman J; Melief CJ; Jager MJ; Toes RE
J Immunol; 2001 Nov; 167(10):5832-7. PubMed ID: 11698457
[TBL] [Abstract][Full Text] [Related]
20. Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner.
Dace DS; Chen PW; Alizadeh H; Niederkorn JY
J Leukoc Biol; 2007 Feb; 81(2):421-9. PubMed ID: 17077163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
